COILED THERAPEUTICS PLC

• ⚠

  Material uncertainty over going concern

  The Directors plan to access further funds during 2025 through the proceeds of the planned sale of the subsidiaries (and/or other financing arrangements) and have reasonable expectations that sufficient cash will be raised through the proceeds of the planned sale of the subsidiaries (and/or other financing arrangements) to fund the planned operations of the Group for a period of at least 12 months from the date of approval of these financial statements. The funding requirement indicates that a material uncertainty exists which may cast significant doubt over the Group's and Company's ability to continue as a going concern, and therefore its ability to realise its assets and discharge its liabilities in the normal course of business.

1. COILED THERAPEUTICS PLC 2026-03-26 → present
2. ROQUEFORT THERAPEUTICS PLC 2021-12-30 → 2026-03-26
3. ROQUEFORT INVESTMENTS PLC 2020-08-17 → 2021-12-30

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

RPG Crouch Chapman LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors plan to access further funds during 2025 through the proceeds of the planned sale of the subsidiaries (and/or other financing arrangements) and have reasonable expectations that sufficient cash will be raised through the proceeds of the planned sale of the subsidiaries (and/or other financing arrangements) to fund the planned operations of the Group for a period of at least 12 months from the date of approval of these financial statements. The funding requirement indicates that a material uncertainty exists which may cast significant doubt over the Group's and Company's ability to continue as a going concern, and therefore its ability to realise its assets and discharge its liabilities in the normal course of business.”

Group structure

1. COILED THERAPEUTICS PLC · parent
   1. Oncogeni Ltd 100% · England · Biotechnology research company
   2. Lyramid Pty Ltd 100% · Australia · Biotechnology research company
   3. Tumorkine Pty Limited 100% · Australia · Dormant

Significant events

• “In September 2024 the Company announced that the European Patent Office and the Japan Patent Office had granted the patents for its Mesodermal Killer ("MK") cell therapy, across 39 counties including the UK, EU and Japan.”
• “On 3 February 2025, Roquefort Therapeutics plc signed a binding share purchase agreement for the sale of its wholly owned subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Ltd for a total consideration of US$10.8 million.”
• “On 10 March 2025, Roquefort Therapeutics plc signed a non-binding term sheet for the proposed sale of its wholly owned subsidiary Oncogeni Ltd, to The Nation Trust Holding LLC for a cash consideration amount of US$12 million.”
• “On 14 March 2025 the Company raised £236,000 by way of a private placing of 15,733,333 new ordinary shares in the capital of the Company at a price of 1.5p per share.”
• “On 17 March 2025 Ajan Reginald and Prof. Sir Martin Evans resigned as CEO, and Non-Executive Director respectively. Dr Darrin M Disley OBE was appointed Interim Managing Director with effect from close of business on 17 March 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

15

last 12 months

Capital events

4

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -37.3%

  £537,322 → £337,112

• Net assets

  -11.1%

  £5,499,543 → £4,889,019

• Employees

  -40%

  10 → 6

• Operating profit

  +42.4%

  -£1,929,754 → -£1,111,515

• Profit before tax

  +37.1%

  -£1,932,233 → -£1,214,569

• Wages

  -63.6%

  £929,019 → £338,440

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers